Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

@article{Reece2009WeeklyAT,
  title={Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.},
  author={Donna Ellen Reece and Vaishali Sanchorawala and Ute Hegenbart and Giampaolo Merlini and Giovanni Palladini and Jean Paul Fermand and Robert A. Vescio and Xiangyang Liu and Yusri Ali Elsayed and Andrew Z Cakana and Raymond L. Comenzo},
  journal={Blood},
  year={2009},
  volume={114 8},
  pages={
          1489-97
        }
}
New treatment options are required for primary systemic AL amyloidosis (AL). This phase 1 dose-escalation component of a phase 1/2 study in relapsed AL aimed to determine the maximum tolerated dose (MTD) of bortezomib once weekly (0.7-1.6 mg/m(2); days 1, 8, 15, and 22; 35-day cycles) and twice weekly (0.7-1.3 mg/m(2); days 1, 4, 8, and 11; 21-day cycles) and assess preliminary hematologic responses. Thirty-one patients with relapsed AL were enrolled across 7 cohorts. Dose-limiting toxicity… 
View on PubMed
bloodjournal.org
154 Citations
Highly Influential Citations
2
Background Citations
34
Methods Citations
4
Results Citations
1

154 Citations

Citation Type

Citation Type

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
TLDR
Both bortezomib dose schedules represent active, well-tolerated regimens in relapsed primary systemic AL amyloidosis and appeared similar in patients with cardiac involvement.
Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis
TLDR
It is demonstrated that BMD is safe and tolerable for Japanese AL patients without severe cardiac damage and the maximum tolerated dose was defined as BOR doses of 1.3 mg/m2 for the twice-weekly schedule.
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
TLDR
Al is frequently rapidly progressive; in patients who had relapsed or progressed following previous conventional therapies, these results suggest that bortezomib may slow the progression of cardiac amyloid with limited toxicity.
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study.
TLDR
Lenalidomide 15 mg/d + M-dex is a new effective combination therapy in patients with newly diagnosed AL amyloidosis and Hematologic and organ responses were both associated with superior EFS rates.
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
TLDR
This prespecified final analysis provides mature response and long-term outcomes data after 3-year additional follow-up since the last report on single-agent bortezomib in relapsed primary systemic amyloid light chain amyloidsosis.
Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement
TLDR
The BD regimen induced high rates of rapid hematologic and organ responses in AL amyloidosis patients, and Baseline Eastern Cooperative Oncology Group performance status and proteinuria were associated with overall survival.
Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex
  • A. Penot, J. Abraham, +11 authors A. Jaccard
  • Medicine
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • 2011
TLDR
Patients with hematologic response after M-Dex have a very good median survival but survival was very poor for refractory patients in the study, as well as in the Italian series.
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)
TLDR
Although unable to save the poorest risk patients, the combination of bortezomib, cyclophosphamide and dexamethasone can achieve a high number of hematologic and cardiac responses, likely improving overall survival and justifying a prospective trial.
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
TLDR
CVD is a highly effective regimen producing durable responses in AL amyloidosis; the deep clonal responses may overcome poor prognosis in advanced-stage disease.
A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis
TLDR
One-third of patients with AL amyloidosis who relapse after HDM/SCT can achieve hematological complete responses (HCRs) with a second SCT, suggesting the feasibility and efficacy of a second HDM-SCT in this setting is explored.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
TLDR
Bortezomib alone or in combination with dexamethasone demonstrated therapeutic activity in patients with multiple myeloma who relapsed after frontline therapy.
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).
TLDR
The combination of thalidomide and dexamethasone is rapidly effective and may represent a valuable second-line treatment for AL, and treatment-related toxicity was frequent, and symptomatic bradycardia was a common adverse reaction.
Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis
The use of bortezomib (B), a first-in-class proteasome inhibitor, administered with or without dexamethasone (D) for treatment of systemic AL amyloidosis, was reported in two small preliminary series…
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
TLDR
Bortezomib plus melphalan-prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy was superior to melphAlan-predisonsone alone.
A phase 2 study of bortezomib in relapsed, refractory myeloma.
TLDR
Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
TLDR
Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
TLDR
In AL patients, the authors saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation.
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.
TLDR
The clonal response rates to CTD reported here are higher than any previously reported nontransplantation regimen in AL amyloidosis, and risk adaptation allows its use in poorer risk patients.
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
TLDR
Findings from this trial indicate that lenalidomide can be effective in treating AL amyloidosis.
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease
TLDR
Preliminary observations on the efficacy of bortezomib in 20 patients with AL amyloidosis whose clonal disease was active despite treatment with a median of 3 lines of prior chemotherapy, including a thalidomide combination in all cases show promise.
...
1
2
3
4
5
...